# A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

> **NCT06212999** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 617 (actual)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** Povorcitinib

## Key facts

- **NCT ID:** NCT06212999
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-30
- **Primary completion:** 2026-12-26
- **Final completion:** 2026-12-26
- **Target enrollment:** 617 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06212999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06212999, "A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06212999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*